Samenvatting: Incyte maakt op EHA 2026 nieuwe positieve resultaten bekend: INCA033989 leidde tot snelle, krachtige en aanhoudende klinische en moleculaire responsen en werd goed verdragen door patiënten met myelofibrose en essentiële trombocytemie
Monday, June 15, 2026 BiopharmaWatch Research 1 min read
Key Takeaway: Incyte announced positive results for INCA033989 at EHA 2026, highlighting its rapid and sustained clinical and molecular responses in patients with myelofibrosis and essential thrombocythemia. The treatment demonstrated good tolerability among patients, marking a significant advancement in therapeutic options for these conditions.
Price reaction · baseline $103.215 (2026-06-15T15:41:00.000Z) · hit during market hours · clean, no other INCY news in the window
day 0 close · peak
-1.2%
Market Sentiment Analysis
POSITIVE FACTORS
INCA033989 showed rapid and powerful clinical responses.
The treatment was well tolerated by patients.
Positive results were presented at EHA 2026.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+44%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
INCB013739
Phase 2 · Type 2 Diabetes
Full Press Release Details
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) heeft vandaag bijgewerkte klinische gegevens bekendgemaakt van twee fase 1-studies waarin de veiligheid, verdraagbaarheid en werkzaamheid werden geëvalueerd van INCA033989. Dit eerste in zijn klasse monoklonaal antilichaam richt zich tegen mutant calreticuline (mutCALR) bij patiënten met mutCALR-positieve myeloproliferatieve neoplasmata (MPN's).
Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal, die als enige rechtsgeldig is.
Frequently Asked Questions
What were the results of INCA033989 at EHA 2026?
INCA033989 showed rapid and powerful clinical and molecular responses.
How was INCA033989 tolerated by patients?
The treatment was well tolerated by patients with myelofibrosis.
What conditions does INCA033989 target?
INCA033989 targets myelofibrosis and essential thrombocythemia.